BERKELEY, Calif., Jan. 24 /PRNewswire/ -- Bayer Pharmaceuticals Corporation, maker of Kogenate(R) FS Antihemophilic Factor (Recombinant), is now accepting applications for its Hemophilia Leadership Development Program, an eight to 10-week paid summer internship program that will begin in June 2007. Applicants should be college students (sophomore through senior year), touched by hemophilia, who can demonstrate a commitment and interest in being a future leader in the hemophilia community. The selected intern(s) will gain firsthand knowledge of the complexities and challenges associated with manufacturing and promoting a recombinant factor VIII (rFVIII) product to the hemophilia community.
"This is the second year for the Bayer HealthCare Hemophilia Leadership Development Program. We are very encouraged about last year's success and the opportunities this internship program continues to present to the hemophilia community," said Terry Tenbrunsel, Bayer HealthCare vice president, sales and marketing.
A robust schedule is planned for this year, including a visit to the manufacturing facility in Berkeley, California, to better understand how rFVIII is made; a review of state and federal legislative activities, classes on leadership, and an introduction to reimbursement, and marketing. The selected participant also will have an opportunity to work on an independent project.
This program was created in response to feedback from hemophilia community members about the pressing need to develop and nurture future leaders in the bleeding disorders community. The paid internship program will take place at the Bayer campus in West Haven, Connecticut. For more information or to apply, call customer service at 888.606.3780 or visit http://www.KogenateFS.com . Applications are due by Wednesday, February 28, 2007, at 11:59 pm ET.
About Kogenate(R) FS Antihemophilic Factor (Recombinant)
Kogenate(R) FS is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate(R) FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate(R) FS. For important safety and use information, please see full Prescribing Information.
About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately one in 5,000 males born in the United States has hemophilia.(1)
About Bayer Pharmaceuticals Corporation
Bayer Pharmaceuticals Corporation ( http://www.bayerpharma.com ) is part of the worldwide operations of Bayer HealthCare AG, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare generated sales amounting to some 9.4 billion euros and employed 33,800 people worldwide in 2005.
The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The new Pharmaceuticals division was established on January 1, 2006, and comprises the former Biological Products and Pharmaceutical divisions. Bayer HealthCare Pharmaceuticals now has three business units: Hematology/Cardiology, Oncology and Primary Care.
Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.